Skip to main content

Timothy M Fan

Assistant Head, Research & Graduate Studies, Veterinary Clinical Medicine

Additional Campus Affiliations

Assistant Head, Research & Graduate Studies, Veterinary Clinical Medicine
Director, Veterinary Clinical Trials Center, Veterinary Clinical Medicine
Professor, Veterinary Clinical Medicine
Professor, Veterinary Teaching Hospital
Professor, Pathobiology
Professor, Biomedical and Translational Sciences
Professor, Carl R. Woese Institute for Genomic Biology
Program Leader, Cancer Center at Illinois, Office of the Vice Chancellor for Research and Innovation
Adjunct Professor, Comparative Biosciences

Recent Publications

Danciu, O. C., Holdhoff, M., Peterson, R. A., Fischer, J. H., Liu, L. C., Wang, H., Venepalli, N. K., Chowdhery, R., Nicholas, M. K., Russell, M. J., Fan, T. M., Hergenrother, P. J., Tarasow, T. M., & Dudek, A. Z. (2023). Phase I study of procaspase-activating compound-1 (PAC-1) in the treatment of advanced malignancies. British Journal of Cancer, 128(5), 783-792. https://doi.org/10.1038/s41416-022-02089-7

Gordon, D. L., Foreman, J. H., Connolly, S. L., Schnelle, A. N., Fan, T. M., & Barger, A. M. (2023). Acute phase protein concentrations following serial procaine penicillin G injections in horses. Equine veterinary journal, 55(5), 916-922. Advance online publication. https://doi.org/10.1111/evj.13886

Holdhoff, M., Nicholas, M. K., Peterson, R. A., Maraka, S., Liu, L. C., Fischer, J. H., Wefel, J. S., Fan, T. M., Vannorsdall, T., Russell, M., Iacoboni, M., Tarasow, T. M., Hergenrother, P. J., Dudek, A. Z., & Danciu, O. C. (2023). Phase I dose escalation study of procaspase-activating compound-1 (PAC-1) in combination with temozolomide in patients with recurrent high-grade astrocytomas. Neuro-Oncology Advances, 5(1), Article vdad087. https://doi.org/10.1093/noajnl/vdad087

Kwon, J. Y., Moskwa, N., Kang, W., Fan, T. M., & Lee, C. (2023). Canine as a Comparative and Translational Model for Human Mammary Tumor. Journal of Breast Cancer, 26(1), 1-13. https://doi.org/10.4048/jbc.2023.26.e4

Ranoa, D. R. E., Sharma, P., Schane, C. P., Lewis, A. N., Valdez, E., Marada, V. V. V. R., Hager, M. V., Montgomery, W., Wolf, S. P., Schreiber, K., Schreiber, H., Bailey, K. L., Fan, T. M., Hergenrother, P. J., Roy, E. J., & Kranz, D. M. (2023). Single CAR-T cell treatment controls disseminated ovarian cancer in a syngeneic mouse model. Journal for ImmunoTherapy of Cancer, 11(5), Article e006509. https://doi.org/10.1136/jitc-2022-006509

View all publications on Illinois Experts

In the news

  • The SHIELD: Target, Test, Tell program combined frequent saliva tests with modeling and an app to keep the University of Illinois Urbana-Champaign campus and surrounding community safe when on-campus operations resumed in fall 2020.
  • A new approach to treating breast cancer kills 95-100% of cancer cells in mouse models of human estrogen-receptor-positive breast cancers and their metastases in bone, brain, liver and lungs. The newly developed drug, called ErSO, quickly shrinks even large tumors to undetectable levels.